Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Repros Therapeutics, Inc.

Latest From Repros Therapeutics, Inc.

Gossamer Partners With Chiesi To Accelerate Seralutinib Development

Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.

Deals Strategy

Viatris And Mapi Knocked Back On Once-Monthly US Copaxone Rival

Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.

Complete Response Letters Value-Added Medicines

Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

Deal Watch Business Strategies

Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade

The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.

Immune Disorders Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Zonagen, Inc.